Insider Buying: Celsion Director Purchases 4,000 Shares of Stock (CLSN)
Celsion (NASDAQ:CLSN) Director Frederick J. Fritz purchased 4,000 shares of the company’s stock on the open market in a transaction dated Thursday, August 14th. The stock was purchased at an average price of $3.20 per share, for a total transaction of $12,800.00. Following the acquisition, the director now directly owns 30,311 shares of the company’s stock, valued at approximately $96,995. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Celsion (NASDAQ:CLSN) remained flat at $3.20 during trading on Thursday. The stock had a trading volume of 66,704 shares. Celsion has a 1-year low of $2.82 and a 1-year high of $6.6216. The stock’s 50-day moving average is $3.25 and its 200-day moving average is $3.40. The company’s market cap is $55.1 million.
Celsion (NASDAQ:CLSN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.32) by $0.06. On average, analysts predict that Celsion will post $-1.37 earnings per share for the current fiscal year.
Separately, analysts at Paradigm Capital raised their price target on shares of Celsion from $12.50 to $13.50 in a research note on Thursday, July 17th. They now have a “buy” rating on the stock.
Celsion Corporation (NASDAQ:CLSN) is an oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.